OneSkin Technologies

Company that designs anti-aging molecules that fights with skin aging

Motivated by a passion to translate science into technology that will positively impact humanity, our founding team noticed that by preventing or reversing aging we can be more efficient in promoting health instead of trying to target specific diseases, that most of the times, are associated with the aging process.

OneSkin has developed a unique platform, based on human models, to screen and validate novel age reversal compounds. Our main target is senescent cells (or zombie cells), which accumulate in different tissues over the aging process and have been associated with numerous age-related diseases such as osteoarthritis, alzheimer and cancer, to name a few.

We have identified a new molecule, named OS-1, and validated its safety through several in vitro studies and human trials, and we are now building the first skin care line focusing on longevity and senescence.

Details last updated 03-Feb-2020

OneSkin Technologies is also referenced in the following:

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.